Wedbush Maintains Outperform, $6 PT on Celidex Therapeutics

Wedbush reiterates its Outperform rating and $6 price target on Celidex Therapeutics CLDX as it believes the primary value drivers for the company are CDX-011 n breast cancer and rindopepimut in glioblastoma. Wedbush notes, "Celldex announced complete accrual of CDX-011 Phase 2b "EMERGE" study in women with GPNMB expressing advanced breast cancer; data anticipated H1:12. The Phase IIb results will guide design of a pivotal study in a patient population with an unmet medical need—in our opinion, triple-negative breast cancer patients. ...Earlier this month Celldex initiated its Phase III “ACT IV” study of rindopepimut in patients with EGFRvIII positive glioblastoma. The study protocol will include a randomized KLH-control, double-blind study of 374 patients at >150 clinical sites internationally." CLDX closed at 2.65 per share on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: ReiterationIntraday UpdateMarketsAnalyst RatingsSmall capsWedbush
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!